Cytokinetics (NASDAQ:CYTK) Given Equal Weight Rating at Morgan Stanley
Morgan Stanley reiterated their equal weight rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report report published on Friday, Marketbeat reports. The firm currently has a $90.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $60.00. Several other equities research analysts have also recently issued […]
More Stories
Ukraine Resumes Strikes on Russian Refineries as Zelenskyy Says ‘We’re Done’ With Trump’s Energy Truce
By Guy Birchall Ukraine has resumed attacks on Russian refineries after Ukrainian President Volodymyr Zelenskyy said Kyiv was “done” complying...
Musk Says US Government Is Controlling Starshield Services Amid Reported Disruptions in Ukraine
By Ryan Morgan SpaceX CEO Elon Musk denied reports that the company curbed its military-oriented Starshield satellite internet service in...
2027 Social Security Payment Boost Announced: 4 Things to Know
By Jack Phillips Social Security officials on Wednesday announced the largest cost-of-living adjustment (COLA) for retired beneficiaries in four years,...
IEA to Accelerate Emergency Release of 100 Million Barrels of Oil
By Jack Phillips The International Energy Agency (IEA) has announced that its member nations will hasten the release of emergency...
US Producer Inflation Posts Sharpest Monthly Gain Since 2022
By Andrew Moran U.S. producer inflation posted its sharpest monthly increase since Russia’s invasion of Ukraine in March 2022, new...
Saudi Arabia Reports Aramco’s Administrative Building on Fire After Being Struck
By Aldgra Fredly A fire broke out at an administrative building owned by Saudi Arabia’s state-owned oil giant after it...